On May 27, 2026, Globus Medical Inc GMED shares fell 3.0% to $82.54. This decline comes in the context of a 52-week range of $51.79 to $101.40, highlighting the stock's recent volatility.
- GF Valueâ„¢ verdict: Current price of $82.54 is 16.1% below the GF Valueâ„¢ of $98.39.
- GF Scoreâ„¢ of 97/100 indicates a strong overall assessment of the company.
- Most notable signal: No insider transactions have occurred in the last 3 months.
Is GMED Overvalued or Undervalued?
Globus Medical Inc's current price of $82.54 is 16.1% below the GF Valueâ„¢ of $98.39, suggesting that the stock is undervalued according to GuruFocus' proprietary metrics. This undervaluation presents a potential opportunity for investors, particularly as the GF Valuation label indicates that GMED is modestly undervalued. However, while the margin of safety appears attractive, it is crucial to consider any inherent risks associated with the company's future performance and market conditions.
GF Valueâ„¢ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Understanding the fundamentals behind this valuation can provide insight into the long-term potential of the stock.
How Does GMED's Valuation Compare to Its History?
| Metric | Current | Historical |
|---|---|---|
| P/E (TTM) | 19.2x | 43.2x |
| Forward P/E | 17.4x | N/A |
Currently, GMED's price-to-earnings (P/E) ratio is 19.2x, which is significantly below its 5-year median P/E of 43.2x. Additionally, the forward P/E of 17.4x further indicates that the stock is trading below its historical valuation levels. This P/E analysis aligns with the GF Valueâ„¢ verdict that the stock is undervalued, reinforcing the potential opportunity presented by the current market conditions.
What Does GMED's GF Scoreâ„¢ Tell Us?
| Metric | Rating |
|---|---|
| GF Scoreâ„¢ | 97/100 |
| Financial Strength | 8/10 |
| Profitability | 9/10 |
| Growth | 10/10 |
| Valuation | 10/10 |
| Momentum | 10/10 |
GMED's GF Scoreâ„¢ of 97/100 indicates a strong overall rating, reflecting solid financial strength (8/10) and exceptional growth prospects (10/10). The valuation and momentum ranks also stand at 10/10, suggesting that the stock is not only well-positioned for potential growth but is also exhibiting positive price trends. However, the company's financial strength, while robust, is the weakest link in this otherwise outstanding profile.
What Are Insiders Doing with GMED Stock?
In the past three months, there have been no insider transactions reported for Globus Medical Inc. This lack of activity may suggest that insiders have not taken any recent positions in the stock, which could indicate a level of uncertainty or stability in the current market conditions. The absence of insider buying, in particular, may raise questions about the confidence of those closest to the company in its short-term outlook.
What This Means for Investors
Based on the GF Valueâ„¢ analysis, Globus Medical Inc GMED is currently undervalued, presenting a potential opportunity for long-term investors. However, it is essential to remain cautious and consider both the company's market position and broader economic factors that may impact its performance.
For the complete analysis, visit the Globus Medical Inc GMED stock page. You can also explore the GF Valueâ„¢ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions
What is GMED's GF Scoreâ„¢?
GMED has a GF Scoreâ„¢ of 97/100, indicating a strong overall assessment of the company based on key performance metrics.
Is GMED overvalued or undervalued?
GMED is currently undervalued, with a GF Valueâ„¢ indicating a 16.1% margin below its estimated fair value.
What is GMED's P/E ratio?
GMED's P/E ratio is 19.2x, which is significantly below its 5-year median P/E of 43.2x, indicating a favorable valuation compared to its historical performance.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
